Madhusoodanan Mottamal to Cell Line, Tumor
This is a "connection" page, showing publications Madhusoodanan Mottamal has written about Cell Line, Tumor.
Connection Strength
0.104
-
Guo S, Zhang C, Mottamal M, Hossain A, Liu J, Wang G. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models. Breast Cancer Res Treat. 2020 Apr; 180(2):359-368.
Score: 0.029
-
Li XL, Sluijter M, Doorduijn EM, Kale SP, McFerrin H, Liu YY, Li Y, Mottamal M, Yao X, Du F, Gu B, Hoang K, Nguyen YH, Taylor N, Stephens CR, van Hall T, Zhang QJ. Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. PLoS One. 2014; 9(11):e108192.
Score: 0.020
-
Zheng S, Zhong Q, Xi Y, Mottamal M, Zhang Q, Schroeder RL, Sridhar J, He L, McFerrin H, Wang G. Modification and biological evaluation of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion. J Med Chem. 2014 Aug 14; 57(15):6653-67.
Score: 0.020
-
Zheng S, Zhong Q, Mottamal M, Zhang Q, Zhang C, Lemelle E, McFerrin H, Wang G. Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents. J Med Chem. 2014 Apr 24; 57(8):3369-81.
Score: 0.019
-
Kim JE, Lee DE, Lee KW, Son JE, Seo SK, Li J, Jung SK, Heo YS, Mottamal M, Bode AM, Dong Z, Lee HJ. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila). 2011 Apr; 4(4):582-91.
Score: 0.016